Trial Profile

A phase I study of KTN-0158 for the treatment of mast cell related inflammatory diseases

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX-0158 (Primary)
Indications Cancer; Inflammation
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Nov 2015 According to a Kolltan Pharmaceuticals media release, the company plans to file an investigational new drug application (IND) for KTN0158 with the FDA in the Q4 of 2015, followed by the initiation of cancer clinical trials in 2016. The company also expects a second IND filing for KTN0158 for neurofibromatosis 1 (NF1) in 2016.
05 Aug 2015 According to a Kolltan Pharmaceuticals media release, this trial is expected to begin in early 2016.
08 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com